source
- Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemiaMarrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
- Novo revamps NovoCare DTC platform as Roche’s Gazyva receives renewed approvalNovo announced a revamp of its direct-to-consumer service, NovoCare, describing it as a reimagined platform for patients. The update includes a refreshed user interface and expanded resources aime…